IMPACT OF DIABETES AND ENDOCRINE DISORDERS ON BREAST CANCER PROGRESSION AND OUTCOMES

Abstract

The complex interplay between metabolic dysregulation and oncogenic pathways has positioned endocrine disorders, particularly diabetes mellitus and thyroid dysfunction, as critical modifiers of breast cancer progression and outcomes. This study employed a mixed-methods experimental design integrating clinical, biochemical, and behavioral data from 354 breast cancer patients, 42% of whom had confirmed endocrine comorbidities. Our quantitative analysis demonstrated that patients with type 2 diabetes exhibited a significantly higher incidence of advanced tumor grade (p < 0.001), greater lymph node involvement (p = 0.004), and reduced progression-free survival, particularly among postmenopausal women. Cox regression models revealed a 1.8-fold increased hazard ratio for mortality in diabetic patients after adjusting for age, stage, and receptor status. Additionally, thyroid dysfunction correlated with variability in estrogen receptor (ER) expression and tumor heterogeneity. Figures 2 through 13 visually captured critical associations between HbA1c levels, survival outcomes, hormonal profiles, and treatment toxicity using hybrid models including bar-line composites, scatter trends, and pie-plot distributions. Qualitative data from structured interviews revealed high rates of treatment non-adherence, increased psychological distress, and polypharmacy-induced side effects among patients with dual diagnoses. The results affirm that endocrine dysregulation significantly impacts breast cancer biology and therapy outcomes. These findings underscore the urgent need for integrated oncologic-endocrine clinical models to optimize care pathways, personalize treatment strategies, and improve survival rates for patients navigating the dual burden of breast cancer and metabolic-endocrine disorders.